Lu KH - Search Results

1

Normal Risk Ovarian Screening Study: 21-Year Update.

Han CY, Lu KH, Corrigan G, Perez A, Kohring SD, Celestino J, Bedi D, Bedia E, Bevers T, Boruta D, Carlson M, Holman L, Leeds L, Mathews C, McCann G, Moore RG, Schlumbrecht M, Slomovitz B, Tobias D, Williams-Brown Y, Bevers MW, Liu J, Gornet TG, Handy BC, Lu Z, Bedia JS, Skates SJ, Bast RC Jr. Han CY, et al. Among authors: lu z, lu kh. J Clin Oncol. 2024 Apr 1;42(10):1102-1109. doi: 10.1200/JCO.23.00141. Epub 2024 Jan 9. J Clin Oncol. 2024. PMID: 38194613

2

Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy.

Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Lu KH, et al. J Clin Oncol. 2000 Jul;18(14):2728-32. doi: 10.1200/JCO.2000.18.14.2728. J Clin Oncol. 2000. PMID: 10894872

3

Early detection of ovarian cancer: promise and reality.

Bast RC Jr, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Bast RC Jr, et al. Cancer Treat Res. 2002;107:61-97. doi: 10.1007/978-1-4757-3587-1_3. Cancer Treat Res. 2002. PMID: 11775462 Review. No abstract available.

4

Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.

Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Tanyi JL, et al. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45. Clin Cancer Res. 2003. PMID: 14506139

5

Heterogeneity of stage IIIA endometrial carcinomas: implications for adjuvant therapy.

Slomovitz BM, Ramondetta LM, Lee CM, Oh JC, Eifel PJ, Jhingran A, Burke TW, Gershenson DM, Lu KH. Slomovitz BM, et al. Among authors: lu kh. Int J Gynecol Cancer. 2005 May-Jun;15(3):510-6. doi: 10.1111/j.1525-1438.2005.15317.x. Int J Gynecol Cancer. 2005. PMID: 15882178 Free article.

6

Correlation of cyclin D1 and cyclin D3 overexpression with the loss of PTEN expression in endometrial carcinoma.

Wu W, Slomovitz BM, Soliman PT, Schmeler KM, Celestino J, Milam MR, Lu KH. Wu W, et al. Among authors: lu kh. Int J Gynecol Cancer. 2006 Jul-Aug;16(4):1668-72. doi: 10.1111/j.1525-1438.2006.00642.x. Int J Gynecol Cancer. 2006. PMID: 16884382

7

Prevention and early detection of ovarian cancer: mission impossible?

Bast RC Jr, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Bast RC Jr, et al. Recent Results Cancer Res. 2007;174:91-100. doi: 10.1007/978-3-540-37696-5_9. Recent Results Cancer Res. 2007. PMID: 17302189 Review.

8

Primary chemoprevention of endometrial hyperplasia with the peroxisome proliferator-activated receptor gamma agonist rosiglitazone in the PTEN heterozygote murine model.

Wu W, Celestino J, Milam MR, Schmeler KM, Broaddus RR, Ellenson LH, Lu KH. Wu W, et al. Among authors: lu kh. Int J Gynecol Cancer. 2008 Mar-Apr;18(2):329-38. doi: 10.1111/j.1525-1438.2007.01002.x. Int J Gynecol Cancer. 2008. PMID: 18334011

9

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.

Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC Jr, Lu K. Moore RG, et al. Gynecol Oncol. 2008 Aug;110(2):196-201. doi: 10.1016/j.ygyno.2008.04.002. Epub 2008 May 21. Gynecol Oncol. 2008. PMID: 18495222 Free PMC article.

10

Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific.

Zhai QJ, Rosen DG, Lu K, Liu J. Zhai QJ, et al. Int J Clin Exp Pathol. 2008 Jan 31;1(6):502-9. Int J Clin Exp Pathol. 2008. PMID: 18787632 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

795 results

Search Page

Filters